MoFo Life Sciences

November 11, 2022 - Agtech, Intellectual Property, Startup, Corporate + Venture Capital
Top Three IP Issues for AgTech Startups
By: Matthew A. Ferry and Edith A. Pierre-Jerome
Innovation, agriculture, and technology took center stage at San Diego’s first AgTech Hackathon. The event took place October 21 – 23 in the city of Escondido, a key farming hub in San Diego County looking to attract agtech startups to the region. The event
... ›
December 04, 2020 - Licensing + Commercial, Corporate + Venture Capital, COVID-19, Startup
Navigating Transaction and Licensing Issues in a COVID-19 World and Raising Angel Investments
By: Jim Krenn, Matthew Karlyn and Michael R. Ward
Session 2 of the GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups was led by Transactions and Licensing partner Matt Karlyn and focused on how to navigate commercial life sciences transactions and licensing issues
... ›
November 17, 2020 - United States, Corporate + Venture Capital, United Kingdom, Startup, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s New Course
By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael R. Ward
MoFo & GSAS Harvard Biotech Club’s new course, “ Legal Topics for Scientists, Entrepreneurs, and Start Ups ,” started on November 11, with more than 100 life sciences graduate students, post-docs, and industry professionals. The Harvard Biotech Club is a student organization that seeks to
... ›
November 09, 2020 - Licensing + Commercial, United States, Corporate + Venture Capital, FDA, United Kingdom, Litigation, Startup, Regulatory, Intellectual Property, Announcements
Legal Topics for Scientists, Entrepreneurs, and Start Ups
By: Michael R. Ward, Anita Choi, Andrew Boyd, Alfredo B. D. Silva, Matthew Karlyn, Jim Krenn and Matthew A. Chivvis
The GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups features a combination of lectures and interactive workshops and is designed for students, post-docs, entrepreneurs, and investors with life sciences and tech backgrounds to learn
... ›
September 22, 2020 - Licensing + Commercial, United States, FDA, Startup, Data Analytics, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s Patent Course Off to a Roaring Start!
By: Michael R. Ward, Matthew Karlyn, Janet Xiao, Matthew A. Chivvis, Jie Zhou, Anna Yuan and Jillian A. Pesin-Fulop
More than 120 life sciences graduate students, post-docs and industry professionals attended the first class of a six part Patent Law Course offered by Morrison & Foerster and the GSAS Harvard Biotech Club on September 16, 2020. The Harvard Biotech Club is a student
... ›
August 16, 2019 - Global, Corporate + Venture Capital, Startup, Healthcare, Announcements
MoFo Hosts “Israeli Innovation in Healthcare” Event in Palo Alto
By: Shiri V. Shenhav, Bradley D. Wine and Shai Kalansky
Last week, Morrison & Foerster’s Israel practice hosted a program in our Palo Alto office titled, “Israeli Innovation in Healthcare,” in collaboration with the Israel Economic Mission to the West Coast. The program featured Professor Karen Avraham, Vice Dean of Tel Aviv University’s Faculty
... ›
January 24, 2018 - United States, Startup, Biotech, Pharma, Regulatory, Intellectual Property
Life Sciences Startups: Patent, FDA Considerations
By: Lisa N. Silverman
Innovator companies at all stages seek patent protection in order to limit market competition. Many early-stage companies seek patent protection with the additional goal of attracting investment. However, even if patent filings are accelerated in order to raise funds, it is important that early-stage
... ›
December 08, 2017 - United States, Corporate + Venture Capital, Startup, Intellectual Property, Financing
Startup diligence is more than ‘basic IP diligence’
By: Desmond P. O'Sullivan
In technology-based startup companies, the strength and integrity of a company’s IP portfolio is a key indicator of its enterprise value. Wise investors closely scrutinize the IP of their targets by doing basic IP diligence. But doing only basic diligence can leave investors blind
... ›